Citius Pharmaceuticals Inc
For the period ended Sep 30, 2024. Filed Dec 27, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Dec 27, 2024
CTXR$0.54+0.5%Stored close · as of Nov 13, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Changes in Stockholders’ Equity
Checking your notes…
| Preferred · Common Stock · Additional Paid-In · Accumulated · Total Citius Pharmaceuticals, Inc. Stockholders’ · Non-Controlling · Total | ||||||||
|---|---|---|---|---|---|---|---|---|
| Stock | Shares | Amount | Capital | Deficit | Equity | Interest | Equity | |
| Balance, September 30, 2022 | $— | 5,848,504 | $5,848 | $232,508,484 | $(129,688,467) | $102,825,865 | $600,380 | $103,426,245 |
| Issuance of common stock for services | — | 4,000 | 4 | 101,996 | — | 102,000 | — | 102,000 |
| Issuance of common stock upon exercise of stock options | — | 1,867 | 2 | 31,265 | — | 31,267 | — | 31,267 |
| Issuance of common stock in registered direct offering, net of costs of $1,201,818 | — | 500,000 | 500 | 13,797,683 | — | 13,798,183 | — | 13,798,183 |
| Stock-based compensation expense | — | — | — | 6,616,705 | — | 6,616,705 | — | 6,616,705 |
| Net loss | — | — | — | — | (32,542,912) | (32,542,912) | — | (32,542,912) |
| Balance, September 30, 2023 | — | 6,354,371 | 6,354 | 253,056,133 | (162,231,379) | 90,831,108 | 600,380 | 91,431,488 |
| Issuance of common stock for services | — | 15,479 | 15 | 284,161 | — | 284,176 | — | 284,176 |
| Issuance of common stock upon exercise of stock options | — | 2,082 | 2 | (2) | — | — | — | — |
| Issuance of common stock offerings, net of costs | — | 875,311 | 876 | 13,802,808 | — | 13,803,684 | — | 13,803,684 |
| Stock-based compensation expense | — | — | — | 11,839,678 | — | 11,839,678 | — | 11,839,678 |
| Merger, net of transaction costs of $2,358,780 | — | — | — | (3,831,357) | — | (3,831,357) | — | (3,831,357) |
| Minority interest from Merger | — | — | — | (3,711,000) | — | (3,711,000) | 3,711,000 | — |
| Net loss | — | — | — | — | (39,425,839) | (39,425,839) | — | (39,425,839) |
| Net loss attributable to noncontrolling interest | — | — | — | — | 287,000 | 287,000 | (287,000) | — |
| Balance, September 30, 2024 | — | 7,247,243 | $7,247 | $271,440,421 | $(201,370,218) | $70,077,450 | $4,024,380 | $74,101,830 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.